BioCentury
ARTICLE | Distillery Therapeutics

Transplant

July 31, 2017 7:18 PM UTC

Mouse studies suggest promoting INDO expression with HDAC inhibitors could help treat idiopathic pneumonia syndrome (IPS) associated with hematopoietic stem cell transplant (HSCT). In a mouse model of HSCT-associated IPS, the pan-HDAC inhibitors pracinostat and Zolinza vorinostat increased lung levels of INDO and decreased IPS disease scores, and pracinostat increased survival, compared with vehicle. Next steps could testing other HDAC inhibitors in the model.

MEI Pharma Inc. and Helsinn Healthcare S.A. have pracinostat (SB939) in Phase II testing for acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). ...